Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476267 (US10874675, Example 8) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 300 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476296 (US10874675, Example 33) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <100 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476276 (US10874675, Example 15) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <100 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476277 (US10874675, Example 16) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <100 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476285 (US10874675, Example 24) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <250 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476287 (US10874675, Example 25) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <250 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476298 (US10874675, Example 35) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <100 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476279 (US10874675, Example 18) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <100 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476289 (US10874675, Example 27) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <500 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476297 (US10874675, Example 34) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | >2.00E+3 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476241 (US10874675, Example 3) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476264 (US10874675, Example 7) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476269 (US10874675, Example 10) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476283 (US10874675, Example 22) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <250 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476292 (US10874675, Example 29) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476294 (US10874675, Example 31) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476268 (US10874675, Example 9) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476274 (US10874675, Example 13) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476284 (US10874675, Example 23) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <250 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476288 (US10874675, Example 26) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <500 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476261 (US10874675, Example 5) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476263 (US10874675, Example 6) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476282 (US10874675, Example 21) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <250 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476240 (US10874675, Example 2) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476242 (US10874675, Example 4) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476273 (US10874675, Example 12) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476280 (US10874675, Example 19) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <250 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476281 (US10874675, Example 20) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <250 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476291 (US10874675, Example 28) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476278 (US10874675, Example 17) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <100 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476295 (US10874675, Example 32) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476275 (US10874675, Example 14) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <100 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476293 (US10874675, Example 30) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM476270 (US10874675, Example 11) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <50 | n/a | n/a | n/a | n/a |
THE SCRIPPS RESEARCH INSTITUTE US Patent | Assay Description Specific Examples of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt's)... | US Patent US10874675 (2020) BindingDB Entry DOI: 10.7270/Q29W0JJ5 | |||||||||||
More data for this Ligand-Target Pair |